AI-driven drug-discovery company using generative AI (Pharma.AI) to design new drug candidates.
AI-driven drug-discovery company using generative AI (Pharma.AI) to design new drug candidates.
Earns from licensing and collaboration deals, where drug companies pay upfront and milestone amounts when a candidate it designed is handed over or reaches a stage, plus fees for access to its software, so revenue is uneven. Its own drug pipeline absorbs most spending.
In one line: A Chinese/global Recursion Pharmaceuticals-style AI drug-discovery biotech.
Moat: narrow (IP / patents, data, process know-how). Proprietary generative-AI models trained on large biological/chemical datasets.
Headquarters: Hong Kong / Cayman Islands · Founded: 2014 · Employees: 317
Size InSilico Medicine Cayman TopCo (3696.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $2.40B, the 373rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$34.62 on 18 Nov 2026.
Performance Over six months the shares fell 32.9%, against -9.7% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 153.0% over the last twelve months (peer median +4.2%); the operating margin is -6.8% (peer median 10.6%).
Valuation It trades at 85.2× forward earnings against a peer median of 26.2× (most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.06B | HK$438M | HK$670M | HK$401M | HK$236M |
| Revenue growth | — | -35% | +67% | +70% | — |
| Gross profit | HK$929M | HK$357M | HK$605M | HK$302M | HK$150M |
| EBITDA | -HK$32.8M | -HK$430M | -HK$244M | -HK$620M | -HK$613M |
| Net income | -HK$2.32B | -HK$2.75B | -HK$133M | -HK$1.66B | -HK$1.74B |
| Free cash flow | HK$342M | -HK$578M | -HK$395M | -HK$232M | -HK$457M |
| Capital expenditure | HK$22.9M | HK$23.2M | HK$7.22M | HK$23.3M | HK$87.9M |
| Total debt | n/a | HK$46.4M | HK$19.9M | HK$17.1M | HK$25.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| InSilico Medicine Cayman TopCo 3696.HK | $2.40B | -33% | +153% | -7% | 85.2× | 37.9% |
| Recursion Pharmaceuticals RXRX | $1.76B | -5% | +56% | -725% | n/a | n/a |
| Schrodinger SDGR | $2.04B | +127% | +5% | -50% | n/a | n/a |
| XtalPi 2228.HK | $2.87B | -34% | +4% | -127% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3696.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.2% | -3.1% | 7th lowest of 21 |
| 6-month return | -32.9% | -9.7% | 4th lowest of 21 |
| Distance from 52-week high | -57.2% | -28.5% | 3rd lowest of 21 |
| Revenue growth (TTM) | +153.0% | +4.2% | highest of 20 |
| Operating margin | -6.8% | 10.6% | 4th lowest of 19 |
| Forward P/E | 85.2× | 26.2× | most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 37.9% | 10.1% | 3rd most demanding of 15 |
| Growth delivered (Del g) | +22.9% | +6.3% | 4th highest of 15 |
| Hurdle (Req g minus delivered) | +15.0 pp | +1.9 pp | 4th most demanding of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 85.2× | 37.9% | +22.9% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 18.2× | n/a | n/a |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 10.6× | 2.3% | +2.9% |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 35.9× | 47.0% | +19.3% |
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | n/a | n/a | n/a |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | n/a | n/a | n/a |
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 6.7× | 14.1% | +0.8% |
| Almirall ALM.MC | Spain | $2.46B | -13% | +24% | 8% | 27.1× | 6.1% | +6.5% |
| Regencell Bioscience RGC | United States | $2.33B | -83% | n/a | n/a | n/a | n/a | n/a |
| Acrobiosystems 301080.SZ | China | $2.31B | +65% | +29% | 17% | 55.2× | 41.3% | +27.7% |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.49B | -24% | -14% | 16% | 27.6× | 3.4% | +4.8% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | n/a | -2.5% | -5.8% |
| IDEAYA Biosciences IDYA | United States | $2.56B | -11% | -83% | -1,267% | n/a | n/a | n/a |
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | n/a | n/a | n/a |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 25.0× | 26.7% | +6.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% | +0.3% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% | -1.5% |
| BioArctic BIOA-B.ST | Sweden | $2.66B | -9% | -46% | 22% | 52.9× | 25.5% | +100.1% |
| Hybio Pharmaceutical 300199.SZ | China | $2.68B | -8% | +70% | 31% | 44.7× | 37.4% | +6.1% |
| Betta Pharmaceuticals 300558.SZ | China | $2.70B | -15% | +16% | 11% | 38.0× | 23.2% | +14.0% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |